Mor, Adi http://orcid.org/0009-0003-5200-1638
Friedman, Scott
Hashmueli, Sharon
Peled, Amnon
Pinzani, Massimo
Frankel, Matthew
Safadi, Rifaat
Article History
Accepted: 17 April 2024
First Online: 1 June 2024
Declarations
:
: This study was supported by Chemomab Therapeutics Ltd. Chemomab had the opportunity to review the manuscript for factual accuracy; the authors maintained full control of the manuscript and determined the final content.
: SF served as a consultant for 89 Bio, Amgen, Axcella Health, Blade Therapeutics, Bristol Myers Squibb, Can-Fite Biopharma, Casma Therapeutics, Chemomab, Escient Pharmaceuticals, Forbion, Galmed, Gordian Biotechnology, Glycotest, Glympse Bio, In sitro, Morphic Therapeutics, North Sea Therapeutics, Novartis, Ono Pharmaceuticals, Pfizer Pharmaceuticals, Scholar Rock, and Surrozen. He holds stock in Blade Therapeutics, Escient, Galectin, Galmed, Genfit, Glympse, Hepgene, Lifemax, Metacrine, Morphic Therapeutics, Nimbus, North Sea Therapeutics, Scholar Rock, and Surrozen. AP has served as a consultant for Chemomab Therapeutics Ltd. MP has served as a consultant for Astra Zeneca, Boehringer Ingelheim, Chemomab, Dicerna, Galecto, LimmaTech Biologics, Promethera, Resolution Therapeutics, and Takeda. He is a cofounder, consultant, and shareholder of Engitix Therapeutics Ltd and 3P-Sense Ltd. He is a chief medical advisor of Hepatotargets BitBio Ltd. RS has received grant/research financial support, served as a consultant, and participated in speakers’ bureaus for Chemomab Therapeutics Ltd. AM, SH, and MF are full-time employees of Chemomab Therapeutics Ltd and may hold Chemomab stock and/or options.
: All studies were conducted in accordance with the Good Clinical Practice Guideline as defined by the International Conference on Harmonization and the Declaration of Helsinki. All study participants provided written informed consent prior to any study activity. The protocol, amendments, and informed consent forms for the Phase 1a studies were approved by the Tel Aviv Souraski Medical Center ethics committee; for the Phase 1b MASLD study, informed consent forms, protocol and amendments were approved by the Hadassah Medical Center institutional review board. Ethics committee approval numbers: TLV-0251-17, 0824-18-TLV , 0117-18-HMO,
: All subjects signed informed consent to participate in the study.
: Not applicable.
: Chemomab Therapeutics, Ltd is committed to responsible sharing of data from clinical trials sponsored by Chemomab. This includes summary and anonymized individual patient data, as well as other information (e.g., protocols). Requests for data from any qualified researchers who engage in rigorous, independent scientific research will be considered as long as the clinical trial data are not part of an ongoing or planned regulatory submission. Original data will be available for 5 years, beginning 3 months after approval of the study drug for use in patients. Send data access proposals to Medinfo@chemomab.com.
: Not applicable.
: AM, SF, SH, AP, MP, and RS participated in the study concept and design. AM and RS were involved in the data acquisition. AM and SH conducted the statistical analysis. AM, SF, SH, MP, MF and RS interpreted the data. All authors critically reviewed and edited the manuscript and provided final approval.